A reappraisal of the central effects of botulinum neurotoxin type A: by what mechanism?

J Neurochem. 2009 Apr;109(1):15-24. doi: 10.1111/j.1471-4159.2009.05887.x. Epub 2009 Feb 11.

Abstract

Botulinum neurotoxin A (BoNT/A) is a metalloprotease that enters peripheral motor nerve terminals and blocks the release of acetylcholine via the specific cleavage of the synaptosomal-associated protein of 25-kDa. Localized injections of BoNT/A are widely employed in clinical neurology to treat several human diseases characterized by muscle hyperactivity. It is generally assumed that the effects of BoNT/A remain localized to the injection site. However, several neurophysiological studies have provided evidence for central effects of BoNT/A, raising the issue of how these actions arise. Here we review these data and discuss the possibility that retrograde axonal transport of catalytically active BoNT/A may explain at least some of its effects at the level of central circuits.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Axonal Transport / drug effects
  • Axonal Transport / physiology
  • Botulinum Toxins, Type A / administration & dosage*
  • Botulinum Toxins, Type A / pharmacokinetics
  • Botulinum Toxins, Type A / physiology*
  • Catalysis
  • Central Nervous System / drug effects*
  • Central Nervous System / metabolism*
  • Humans
  • Injections, Intramuscular
  • Neuromuscular Diseases / drug therapy
  • Neuromuscular Diseases / metabolism
  • Synapses / drug effects
  • Synapses / metabolism

Substances

  • Botulinum Toxins, Type A